Background: Over 60% of all cancers are diagnosed in patients' ≥65 years. The aim of this study was to ascertain the incidence of adverse drug events (ADEs) causing hospitalisation in older patients with cancer and identify if it differs to that of the general acute older population.
Methods: This prospective observational study was conducted over a 12-month period. Adults (≥16 years) admitted under a specialist tertiary oncology service were studied. The proportion of patients where a probable/certain ADE, according to WHO-UMC causality assessment, caused/contributed significantly to admission were recorded.
Results: 265 participants participated. 54% were female. The median age was 66 (IQR57-72), with 52.5% ≥65 years, 35.5% ≥70 years and 7.5% ≥80 years. Older adults, compared to younger adults, had significantly more comorbidities, 8 (IRQ5-10) vs 5 (IRQ3-6) p < 0.001, and took more medications, 7 (IQR4-10) vs 4 (IQR2-7) p = 0.026. The most common cancers were breast (18.5%), lung (18.5%) and colorectal (9.1%). ADEs occurred in 30.9% (n = 82). 27.9% (n = 74) caused/contributed significantly to admission. ADE occurrence had no relationship to age p = 0.960, gender p = 0.399, length of stay p = 0.537, or medication number p = 0.533. ADEs incidence was similar in older and younger adults for both non-cancer drugs (14.4% vs 9.5%, p = 0.141) and cancer specific treatments (13.7% vs 15.9%, p = 0.469). The most commonly reported ADEs were neutropenia with associated infection in 23%, nausea/vomiting in 18.9% and major constipation in 17.6%.
Conclusions: Approximately 1 in 4 acute admissions in adult patients with cancer are ADE related. ADEs are caused by non-cancer drugs as frequently as cancer specific treatments in both older and younger adults. Older cancer patients experience ADEs at similar frequency to their younger counterparts. The ADE rates reported here for older cancer patients are higher than those previously reported for the general acute population.
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